Loading chat...
HI HCR29
Concurrent Resolution
Status
2/15/2018
Primary Sponsor
Nicole Lowen
Click for details
AI Summary
-
Urges the U.S. Food and Drug Administration, U.S. Surgeon General, and Hawaii's Congressional Delegation to consider requiring warning labels on products containing oxybenzone addressing human health risks.
-
Cites research indicating oxybenzone can cause estrogen buildup leading to endometriosis and breast cancer, acts as a hormone mimicker, accumulates in body tissues, and is transferred through breast milk.
-
Notes a 2015 study linked in-utero oxybenzone exposure to Hirschsprung's disease, a neonatal intestinal abnormality, with no established safe exposure level.
-
States the FDA's most recent oxybenzone safety evaluation occurred in 1999, and current 2011 labeling rules do not include warnings about oxybenzone health risks.
-
Directs transmission of certified resolution copies to FDA Commissioner, U.S. Surgeon General, Hawaii Congressional Delegation members, and state Health and Commerce and Consumer Affairs Directors.
Legislative Description
Urging The United States Food And Drug Administration, The United States Surgeon General, And Hawaii's Congressional Delegation To Consider Whether Products Containing Oxybenzone Should Include A Warning Label That Addresses Human Health Concerns.
Health
Last Action
Report adopted; referred to the committee(s) on FIN with none voting aye with reservations; none voting no (0) and Representative(s) Souki excused (1).
3/28/2018